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ate for patient reporting in their current form, due to mixing of symptom attributes 
within items and technical jargon. The committee determined that measured attributes 
for each symptom should include frequency, severity, and activity interference. Ques-
tions and response options were standardized, along with plain language terms for 
each symptom. a web-based platform was developed for administering the new PRO-
CTCAE items. CONCLUSIONS: In response to a charge from the NCI, the PRO-
CTCAE, a patient version of the CTCAE system, has been developed. The prototype 
is undergoing testing to assess validity, usability, and logistical feasibility in a variety 
of cancer care settings. The PRO-CTCAE system has the potential to enhance adverse 
event reporting by integrating patient experiences and can foster consistency of data 
collection methods across studies.
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OBJECTIVES: Diagnosis and treatment of cancer entail a considerable amount of 
distress which in a large percentage of patients would require psychooncological treat-
ment (POT). There is though a lack of precise and economic measures for assessing 
the need for POT. Its detection in clinical routine often depends on procedural and 
personnel conditions. The aim of the study was the development and implementation 
of a patient-reported outcome tool for the screening of distress. a further aim is the 
construction of a computer-adpative testing (CAT) version. METHODS: 115 breast 
cancer outpatients attending the Department of Gynaecology at Innsbruck Medical 
University were consecutively included in a pilot study. Logistic regression analysis 
and ROC analyses identiﬁ ed the most predictive items from a set of questionnaires 
(EORTC-QLQ-C30, HADS, and Hornheide Screening Instrument) and other addi-
tional questions. The development of the CAT screening tool comprises generating an 
item bank, developing the CAT-algorithm and applying and implementing the CAT 
in clinical practice. RESULTS: Data from 105 breast cancer patients (mean age 58.8, 
SD 12.3) were analyzed. The EORTC QLQ-C30 scales Emotional Functioning and 
Role Functioning as well as the yes–no question after psychiatric/psychological/psy-
chotherapeutic treatment at any point in lifetime showed high predictive power with 
regard to need for POT (AUC = 0.88; CI 95% 0.82–0.95). The generation of the item 
bank resulted in 52 prelinimary items which will be subjected to further analyses. 
CONCLUSIONS: The implementation of precise and effective measures for POT 
needs is essential for providing comprehensive and high-quality cancer care. CAT 
methodology contributes to the reduction of patient burden and assessment duration, 
and increases efﬁ ciency as well as measurement precision.
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OBJECTIVES: Computer-adaptive testing (CAT) is an advanced method for measur-
ing patient-reported outcomes. With help of an algorithm, CAT selects the items most 
relevant for an individual patient from an item bank. Our study aim was the develop-
ment of a CAT version of the EORTC QLQ-C30 Fatigue scale, its implementation in 
a software package, and its use in daily clinical routine. METHODS: Our project is 
part of a large project on CAT development conducted by the EORTC Quality of Life 
Group. To set up an initial English fatigue item list, an extensive literature research 
was performed. These items were reﬁ ned through multistage expert reviews, translated 
to German, Danish, Spanish, French, and Dutch, and ﬁ lled in by a pilot patient sample 
to collect feedback. In a next step, a large patient sample is recruited for all language 
versions to gain data for development of the item bank and the CAT algorithm. 
RESULTS: Literature research resulted in 588 fatigue items, from which 44 were 
selected after comprehensive expert reviews. Based on feedback from 52 oncological 
patients, wording and translation of several items were revised. Data have been col-
lected from about 1200 patients. Preliminary results of the CAT-analysis will be 
presented. CONCLUSIONS: By generating individually tailored item sets, CAT 
reduces patient burden and assessment duration, and increases measurement precision. 
In addition, electronic data capture increases data quality and reduces the amount of 
human resources required for data collection.
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OBJECTIVES: To compare the economic and patient-reported outcomes between 
outpatient home-based and inpatient hospital-based chemotherapy in advanced 
colorectal cancer patients. METHODS: A total of 80 patients from Severance Hospital 
in Seoul, Korea, who had stage III colorectal cancer and underwent home-based (n = 
40) or hospital-based chemotherapy (n = 40) with a FOLFOX regimen between 
January 2007 and April 2008 were enrolled. Patient satisfaction data were collected 
by a self-administered questionnaire survey. Based on hospital charge records, average 
cost (in 2008 Korean won) per chemotherapy session was estimated and compared 
between home- and hospital-based chemotherapy from a societal perspective. 
RESULTS: Patients receiving chemotherapy at home showed higher satisfaction with 
their treatment (mean satisfaction score: 3.58 ± 0.15, 5-point Likert-type scale, with 
a higher score indicating higher satisfaction) than did those treated at the hospital 
(3.23 ± 0.21; P < 0.01). After adjusting for differences in baseline characteristics 
between the two groups using multivariate analysis, those receiving home-based che-
motherapy still showed signiﬁ cantly higher satisfaction than those undergoing hospi-
tal-based therapy (β = 0.271, P < 0.001). Additionally, home-based therapy reduced 
the cost per chemotherapy session by 16.6%, compared with hospital-based treatment 
(1,694,216 vs. 2,030,383 Korean won [KW], 1200 KW ≈ 1 US dollar). The largest 
cost reduction was attributable to medical costs (−201,122 KW), followed by care-
giver’s opportunity costs (−135,000 KW). CONCLUSIONS: Higher satisfaction and 
lower economic cost for home-based chemotherapy suggests that home-based chemo-
therapy could be a popular and cost-effective treatment option for colorectal cancer 
patients who are eligible for home-based chemotherapy.
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OBJECTIVES: Patients’ own assessment of the impact of anticancer therapy has been 
considered important from a patient, physician, payor, and regulatory perspective. 
Approximately 12% of all oncology clinical trials list at least one patient-reported 
outcome (PRO) measure; 50% of these are phase II trials. Use and publication of PROs 
results were systematically reviewed for breast, colorectal, ovarian, and non-small cell 
lung cancer (NSCLC). METHODS: Citeline’s TrialTrove database was searched for 
oncology trials that included PROs and were planned, ongoing or completed as of 
October 2009. Speciﬁ c trial factors examined include phase, disease type, location, 
sponsorship, type of PRO instrument(s), and publication of PRO endpoint results. 
RESULTS: Of the 5483 phase II trials retrieved for breast, colorectal, ovarian, and 
NSCLC, 9% listed PROs. PRO measures were more frequently included in NSCLC 
(13%) and ovarian cancer (10%) than in breast (7%) or colorectal (8%) cancer phase 
II trials. Fifty-two percent of these trials were sponsored by industry, with 25% and 
19% being sponsored by academic and cooperative groups, respectively. One-third of 
the trials were conducted in the United States only. PROs were most frequently measured 
with the EORTC and FACT series of questionnaires. Phase II PRO results were pub-
lished 24%, 36% and 39% of the time for breast, ovarian, and NSCLC, respectively, 
and only 18% of the time for colorectal cancer. This compares with an overall publica-
tion frequency for PRO trials (any end points) of 58% to 67% which was highest in 
NSCLC. PRO results were published more frequently for trials conducted in Asia or 
Europe. However, trial sponsorship did not impact publication frequency. CONCLU-
SIONS: PROs are infrequently assessed in phase II cancer trials. PRO measures were 
most frequently included in NSCLC trials and sponsored by industry. PRO results were 
published less frequently than other end points in these trials. Publication frequency 
differed by tumor type and trial location.
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OBJECTIVES: The aim of this study was to determine the smallest changes in health-
related quality-of-life (HRQOL) scores in the European Organization for Research 
and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and the 
EORTC Brain Cancer Module (QLQ-BN20), which could be considered as clinically 
meaningful in brain cancer patients. METHODS: World Health Organization (WHO) 
performance status (PS) and the Mini Mental State Examination (MMSE) were used 
as clinical anchors appropriate to related subscales to determine minimal clinically 
important differences (MCID) in HRQOL change scores (range 0–100) in the EORTC 
QLQ-C30 and QLQ-BN20. a threshold of 0.2SD (small effect) was used to exclude 
anchor-based MCID estimates considered too small to inform interpretation. 
RESULTS: Based on WHO PS, our ﬁ ndings support the following integer estimates 
of the MCID for improvement and deterioration, respectively: physical functioning 
(6, 9), role functioning (14, 12), cognitive functioning (8, 8), global health status (7, 
4*), fatigue (12, 9), and motor dysfunction (4*, 5). Anchoring with MMSE, cognitive 
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functioning MCID estimates for improvement and deterioration were (11, 2*) and 
those for communication deﬁ cit were (9, 7). The estimates with asterisks were less 
than the 0.2 SD threshold and were therefore excluded from our MCID ranges. Our 
MCID estimates therefore range from 5 to 14. CONCLUSIONS: These estimates can 
help clinicians to interpret the clinical relevance of changes in HRQOL over time and, 
in conjunction with other measures of efﬁ cacy, help to assess the value of a health-care 
intervention. The ﬁ ndings also indicate that more sensitive measures may be needed 
to detect certain changes. Furthermore, the estimates can be useful in determining 
sample sizes in the design of future clinical trials.
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OBJECTIVES: To clarify the details of psychosocial health status, the effects and 
related costs of psychosocial group intervention in post-breast cancer surgery patients. 
METHODS: Structured psychosocial group intervention (90 min/week × ﬁ ve sessions) 
was conducted for 66 patients aged 20–79 years who were receiving breast cancer 
treatment at three hospitals in Japan (intervention group). The intervention was 
conducted 2 weeks to 3 months after radical surgery. HRQOL and psychosocial 
function were investigated prospectively for outcome. The survey included 1) EORTC 
QLQ-C30 for HRQOL; and 2) POMS, MAC scale, and a characteristic self-efﬁ cacy 
scale for psychosocial function. It was conducted at registration, week 4 (group 
therapy conclusion), and month 6. Prior to the intervention study, a group that fulﬁ lled 
the same eligibility criteria but did not receive psychosocial group intervention was 
studied (n = 116; nonintervention group). The same outcomes were measured and 
compared using multivariate analysis adjusted for disease stage, chemotherapy, and 
hospital. Direct medical costs were obtained from receipt data, and information on 
travel expenses, direct nonmedical costs, and indirect costs (productivity costs) were 
collected simultaneously with the HRQOL survey. RESULTS: In HRQOL and psy-
chosocial function, an intervention effect was seen in fatalism (MAC_F) only. In a 
subgroup analysis by hospital, effects of cognitive function were seen in HRQOL 
(EORTC_CF), tension-anxiety (POMS_TA), helplessness/hopelessness (MAC_H), and 
fatalism (MAC_F). However, these effects were not seen at 6 months. Total medical 
costs including indirect costs during the 6 months were ¥840,000 for the intervention 
group and ¥750,000 for the nonintervention group. CONCLUSIONS: Structured 
psychosocial group intervention for post-breast cancer surgery patients had a uniform 
effect in improving HRQOL and psychosocial function. It is signiﬁ cant that a beneﬁ t 
was obtained in the early postoperative period when HRQOL is most easily damaged. 
Medical costs did not differ signiﬁ cantly between the groups.
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OBJECTIVES: For the last two decades, QL has been increasingly assessed in the 
EORTC. a detailed database review of all completed and ongoing EORTC QL studies 
has been undertaken. METHODS: A database of all EORTC QL clinical trial proto-
cols was established in 2000. This regularly updated database comprises all trials 
where QL has been included as an end point. It summarizes details of closed and 
ongoing trials, QL tools used, assessment timing, disease and treatment types, compli-
ance, and published outcomes. These were examined and reported. RESULTS: The 
database contains over 128 EORTC clinical trial protocols over a 15-year period 
between 1995 and 2010 which included a QL component. This is an average of eight 
new clinical trials with QL per year with only two having QL as a primary end point. 
The QLQ-C30 was the instrument of choice in 85% of trials. In the last decade, 15 
EORTC clinical groups have been recruiting patients. The majority of trials were 
conducted by the radiotherapy, brain and breast groups. Over 20,000 patients, mostly 
from Belgium, France, Germany, and the The Netherlands, have been entered into 
closed and ongoing multinational trials. Typically, EORTC trials are conducted across 
an average of 12 countries which include over 85 centers and often involve only a 
single trial. Several early EORTC trials experienced lower than ideal compliance. This 
presents a major challenge for the EORTC, but trials in the last 6 years have demon-
strated signiﬁ cantly improved compliance. Most QL studies were published as separate 
papers from the main clinical paper, and over 80% were published in high-impact 
factor journals (IF > 12). CONCLUSIONS: QL is now a major component of cancer 
clinical trials, an almost standard secondary end point. This suggests that researchers 
in the European context increasingly acknowledge the importance of patient-reported 
outcome assessments for evaluating cancer therapeutic modalities.
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OBJECTIVES: To compare hematological toxicity, costs, health-related quality of life 
(HR-QOL), and outcomes observed in real life in the Belgian non-Hodgkin lymphoma 
(NHL) population receiving 90Y-Zevalin, with model-predicted data at reimburse-
ment on the basis of a clinical trial in heavily pretreated NHL. METHODS: Twelve 
of the 13 centers trained for 90Y-Zevalin administration at the time of reimbursement 
approval participated. All consecutive patients receiving 90Y-Zevalin for Rituximab-
relapsed/refractory NHL were included in this 1-year, multicenter, prospective, obser-
vational study. QOL assessments, based on a generic (EQ-5D) and a disease-speciﬁ c 
(FACT-LYM) questionnaire, were performed at baseline (date of ﬁ rst administration 
Rituximab), day 8, month 1, 2, and 3 after baseline. Costing (c, 2008) was based on 
ofﬁ cial tariffs and observed resource use. RESULTS: Over the 2-year recruitment 
period, 30 patients were included. Only one1 patient received hematopoietic growth 
factor prophylaxis. Hematological toxicity occurred in 79% of patients, but was 
generally mild. Grade IV neutropenia was reported in 16% of patients (35% pre-
dicted), grade IV thrombocytopenia in 23% (9% predicted), and grade IV anemia was 
not reported (4% predicted). EQ-5D as well as FACT-LYM assessments suggested no 
signiﬁ cant changes in HR-Qol over the study period and no impact of hematological 
toxicity on HR-Qol. The average total cost from the health-care payer perspective, 
covering costs of drugs, drug administration setting, and prophylaxis, mounted to 
c16,886 (Standard error 79 c). Hematological toxicity added c1191 (Standard error: 
c528), constituting 7% of total costs (18,076 c). Observed costs were within 2% from 
predicted costs. Median time to progression (TTP) was 11.7 months (6.8 months 
predicted). CONCLUSIONS: This observational study conﬁ rmed the predicted toler-
ability proﬁ le, costs and outcomes associated with 90Y-zevalin in a real-life patient 
population. Furthermore, the patient numbers treated with 90Y-Zevalin in real life 
were lower than anticipated (maximum 100 predicted).
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OBJECTIVES: To assess the clinical use of HRQoL instruments in RCTs in cervical 
carcinoma and evaluate pertinent methodological issues. METHODS: RCTs investi-
gating HRQoL beneﬁ t of therapies in cervical carcinoma in adult females, published 
in English language were included. Cochrane Central Register of Controlled Trials, 
MEDLINE and EMBASE were searched from inception to 2010. Two reviewers 
independently assessed the trials for inclusion and performed extraction. RESULTS: 
Of the 96 RCTs identiﬁ ed, 13 RCTs met the inclusion criteria. Ten trials compared 
different chemotherapy regimens in ﬁ rst- to third-line treatment. The most commonly 
used QoL instrument was Functional Assessment of Cancer Therapy (FACT-G) (46% 
trials). Alternatively, cancer-speciﬁ c European Organization for Research and Treat-
ment of Cancer-Quality of Life Questionnaire-Core 30 (EORTC QLQ-30), SF-36, and 
Linear Analogue Scale Assessment (LASA 100 mm) were used either alone or in 
conjunction with the Brief pain Inventory (BPI). Only one trial reported HRQoL as a 
primary objective. HRQoL results were presented adequately in 61% trials which were 
analyzable. Statistically signiﬁ cant differences in HRQoL between treatment groups 
were studied in 69% studies, but the clinically meaningful difference was examined 
in only one study. Prognostic value of QoL was assessed in only two trials (15%). 
Most widely observed methodological issues included lack of priori hypothesis (92% 
studies) and lack of methods to deal with missing data (85%). Other issues included 
lack of details on domain, variability in time points of administration of a tool, and 
patient’s noncompliance, reported in ~60% studies. CONCLUSIONS: HRQoL is 
included as an outcome in the studies investigating therapies in cervical carcinoma but 
clinically meaningful interpretations of HRQoL results are rarely considered. The 
methodological shortcomings in the assessment and analysis of HRQoL outcomes 
should be examined further to derive clinically meaningful and correlating evidence.
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OBJECTIVES: Maintenance therapy can delay progression and prolong survival in 
metastatic non-small cell lung cancer (mNSCLC). The impact of treatments for 
mNSCLC on patient quality-of-life (QoL) is an important consideration, as treatment 
is noncurative and QoL in this population is already compromised. The SATURN 
study demonstrated that, compared with placebo, erlotinib maintenance therapy 
improved progression-free survival and overall survival by 41% and 23%, respec-
tively. The impact of erlotinib maintenance therapy on QoL was also evaluated as a 
secondary end point. METHODS: Patient QoL was assessed until disease progression 
or withdrawal using the Functional Assessment of Cancer Therapy-Lung (FACT-L) 
questionnaire. Disease progression was assessed radiographically at regular intervals, 
often diagnosed prior to symptomatic progression. Patient QoL was analyzed in terms 
